Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib in BRCA1/2 wild-type advanced breast cancer and other solid tumors
NCT02401347Phase 2Completed
- Sponsor
- Melinda Telli
- Start
- Aug 2015
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of talazoparib in triple-negative breast cancer (TNBC), breast cancer, solid tumor, sponsored by Melinda Telli. Started Aug 2015; status: completed.
02
Drugs
talazoparib
03
Conditions
triple-negative breast cancer (TNBC)breast cancersolid tumor
Beyond the preview
Go deeper on NCT02401347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02401347.